ESC 365 - Understanding the clinical benefit of icosapent ethyl: insights from REDUCE-IT

Open Access

Understanding the clinical benefit of icosapent ethyl: insights from REDUCE-IT

Session: From risk assessment to action: the role of icosapent ethyl in cardiovascular risk management

Topic: Secondary Prevention

Speaker: Doctor H. Contractor (Manchester, GB)

Sponsored by Amarin

Event: ESC Preventive Cardiology 2025

Congress Presentation

Add to my library

About the speaker

Doctor Hussain Contractor

Manchester University Hospitals, Manchester (United Kingdom of Great Britain & Northern Ireland)

1 presentation

1 follower

3 more presentations in this session

Clinical Case Introduction

Speaker: Professor V. Aboyans (Limoges, FR)

U-Prevent: a personalized approach to cardiovascular risk management

Speaker: Doctor J. Dorresteijn (Utrecht, NL)

Key takeaways: addressing residual cardiovascular risk with proven therapies

Speaker: Professor G. De Ferrari (Turin, IT)

Access the full session

From risk assessment to action: the role of icosapent ethyl in cardiovascular risk management

Speakers: Doctor H. Contractor, Professor V. Aboyans, Doctor J. Dorresteijn, Professor G. De Ferrari

About the event

ESC Preventive Cardiology 2025

3 April - 5 April 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources